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Background: Aberrant epigenetic profiles are concomitant with a spectrum of developmental defects and
diseases. Role of methylation is an increasingly accepted factor in the pathophysiology of diabetes and its associated
complications. This study aims to examine the correlation between oxidative stress and methylation of β1, β2
and β3-adrenergic receptors and to analyze the differential variability in the expression of these genes under
hyperglycemic conditions.
Methods: Human retinal endothelial cells were cultured in CSC complete medium in normal (5 mM) or high
(25 mM) glucose to mimic a diabetic condition. Reverse transcription PCR and Western Blotting were performed
to examine the expression of β1, β2 and β3-adrenergic receptors. For detections, immunocytochemistry was
used. Bisulfite sequencing method was used for promoter methylation analysis. Apoptosis was determined by the
terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay. Dichlorodihydrofluorescein diacetate
(DCFH-DA) assay was used to measure reactive oxygen species (ROS) production in the cells.
Results: β1 and β3-adrenergic receptors were expressed in retinal endothelial cells while β2-adrenergic receptor was
not detectable both at protein and mRNA levels. Hyperglycemia had no significant effect on β1 and β2-adrenergic
receptors methylation and expression however β3-adrenergic receptors showed a significantly higher expression
(p < 0.05) and methylation (p < 0.01) in high and low glucose concentration respectively. Apoptosis and oxidative stress
were inversely correlated with β3-adrenergic receptors methylation with no significant effect on β1 and β2-adrenergic
receptors. β2-adrenergic receptor was hypermethylated with halted expression.
Conclusion: Our study demonstrates that β1 and β3-adrenergic receptors expressed in human retinal endothelial cells.
Oxidative stress and apoptosis are inversely proportional to the extent of promoter methylation, suggesting that
methylation loss might be due to oxidative stress-induced DNA damage.
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Diabetes is a growing epidemic, caused by excess glucose
levels and body’s inability to produce or regulate insulin
[1]. It is predicted that the number of people with dia-
betes will increase from 171 million in 2000 to 366 mil-
lion by 2030 [2,3]. Diabetes is linked to several vascular
pathologies, including severe blindness, atherosclerosis,
stroke and renal failure. The growing number of people
with diabetes suggests that diabetic retinopathy (DR)
and diabetic macular edema (DME) will continue to be
sight threatening diseases. Distinct morphological abnor-
malities in the retinal microvasculature either remain
stable or progress to diabetic macular edema or prolifer-
ative diabetic retinopathy, the leading causes of severe
visual impairment in working-age adults in industrialized
countries [4,5].
In vitro and in vivo studies have revealed that hyper-
glycemic environment induces a number of cellular
changes which affect the function and viability of cells
[6,7]. Changes in the diabetic retina are due to a variety
of factors including high glucose, oxidative stress and
high levels of inflammatory markers [8,9]. Reactive oxy-
gen species (ROS), especially mitochondrial ROS, play a
significant role in modulating the cellular redox status
[10]. Excessive production of ROS and the impairment
of the oxidant/antioxidant balance may in part underlie
the pathogenesis of diabetes and its associated compli-
cations [11]. Actions of such key pathological mediators
of diabetes can lead to dysregulated epigenetic mecha-
nisms that affect chromatin structure and gene expression
profiles [12]. DNA methylation is one of the mechanisms
for the epigenetic control of gene expression and aberrant
DNA methylation patterns of CpG islands can influence
normal transcriptional regulation in various diseases [13].
Beta adrenergic receptors are G protein coupled recep-
tors (GPCRs), initially characterized by Ahlquist in 1948.
[14]. Activation of these receptors takes place at the
transmembrane region, which allows ligand binding and
elicit a range of cellular actions such as phosphorylation
and activation of various signaling pathways [15]. Upon
binding of specific ligands, β1 and β2-adrenergic recep-
tors activate the stimulatory G protein resulting in the
dissociation of G protein subunits αβ from γ. The αβ
subunits are linked to the stimulation of intracellular
adenylyl cyclase, followed by the conversion of adeno-
sine triphosphate into cyclic adenosine monophosphate
(cAMP) and consequently leads to activation of protein
kinase A and phosphorylation of several other substrates
[16,17]. However contrary to β1 and β2-adrenergic re-
ceptors, β3-adrenergic receptor couple through the in-
hibitory G protein (Gi), causing a reduced generation of
cAMP [18]. Work in animal models suggests that ad-
renergic receptor agents may promote corneal wound
healing and it is known that cornea has an abundanceof β-adrenergic receptors in both the epithelium and endo-
thelium of the cornea [19]. Previous studies demonstrate
that β-adrenergic receptors agonists have positive effects
on the retina by reducing the inflammatory markers
[20-22]. Studies on rats have demonstrated that highly se-
lective agonists for β-ARs partially reversed obesity [23]
and insulin resistance [24]. Similarly β-adrenergic receptor
agonists like isoproterenol inhibits the formation of degen-
erative capillaries, prevents apoptosis of cells and reduces
tumor necrosis factor (TNF) while anatagonists increase
retinal dysfunction [25]. The role of Beta-adrenergic recep-
tor agonists and antagonists in the treatments of glaucoma,
diabetic retinopathy, and their potential mechanisms of ac-
tions, are still under investigation.
Type 2 diabetes is a multifactorial disease caused by a
number of genetic, epigenetic and environmental factors
[26]. In mammalian cells, DNA methylation takes place
at cytosine in CpG dinucleotides and has been associ-
ated with transcriptional silencing [27]. Recent studies
have shown that epigenetic modifications such as DNA
methylation and histone modifications may affect the
pathogenesis of type 2 diabetes [28,29]. Differential gene
expressions show dynamic alterations in gene transcrip-
tion and mRNA stability that can be influenced by the
epigenetic modification of the genome in response to
chronic hyperglycemic stress [30,31]. A number of stud-
ies have evaluated the epigenetic mechanisms in various
developmental defects and diseases. Oxidative stress and
alterations in DNA methylation have also been observed
in diabetes, but no clear correlation between these events
has been demonstrated until now. Very little research has
focused on the epigenetics of adrenergic receptors in the
eye and its relation to diabetic retinopathy. In the present
study, we sought to determine which subtypes of Beta-
adrenergic receptors that were expressed in retinal endo-
thelial cells, and assessed the hyperglycemia induced dif-
ferential expression. In addition we analyzed the role of
oxidative stress modulating CpG methylation in the pro-
moters of β1, β2 and β3-adrenergic receptors.
Methods
Cell culture
Human retinal endothelial cells (Cell Systems, ACBRI
181) were cultured in CSC complete medium (Cell Sys-
tems, 4Z0-500) supplemented with 10% serum, 1% Peni-
cillin Streptomycin and animal derived growth factors.
Cells were grown in attachment factor-coated dishes
containing normal (5 mM, 0.9008 g/L) and high
(25 mM, 4.5 g/L) glucose. When the cell reached 80%
confluence, they were passaged with the use of a passage
reagent group, supplied with the complete medium kit
(Cell systems). The cells between 3-6 passages were used
in all experiments and grown in 5% CO2 at 37°C. Media
was changed every 2 to 3 days.
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The beta-adrenergic receptors were identified as described
earlier [32], with minor changes. Retinal endothelial cells
were seeded (50,000/well) onto 6-well plates with sterile
coverslips in medium containing 5 mM (normal glucose)
and 25 mM (high glucose). They were allowed to attach
and proliferate in the respective medium for 2 days. The
cells were fixed with cold methanol for 10 minutes at -20°C,
rinsed twice with PBS, blocked at room temperature with
0.5% Tween (v/v) and 2% BSA (w/v) in PBS (blocking solu-
tion) for 1 hour and rinsed again twice with PBS. The wells
were incubated overnight with primary antibodies against
β1 adrenergic receptor (Santa Cruz, sc-568), β2-adrenergic
receptor (Santa Cruz, sc-569) and β3-adrenergic receptor
(Santa Cruz, sc-1472) in blocking solution at a dilution
of 1:100. Anti-β-actin (sc-7210) antibodies were used as
positive control. The following day, the cells were
washed twice with PBS and incubated for 1 hour in
dark room with secondary antibodies conjugated with
fluorescein isothiocyanate (FITC) in blocking solution
at a dilution of 1:200. After rinsing twice with PBS, the
coverslips were mounted with antifading medium (Life
Technologies, ProLong Gold) and analyzed under fluo-
rescence microscope.
RT PCR
Total RNA from Human retinal endothelial cells (HREC)
was isolated using RNeasy commercial kit (Qiagen, cat no
74104) according to the manufacturer’s protocol and quan-
tified spectrophotometrically. First-strand cDNA was syn-
thesized with 1 μg of each DNA free total RNA, using
iScript reverse transcription supermix (Biorad USA, cat no
170-8841) containing Moloney murine leukemia virus re-
verse transcriptase, RNase inhibitor, dNTPs, oligo-(dT),
random primers, buffer, MgCl2 and stabilizers. No-RT con-
trol with the same amount of RNA but without RT was in-
cluded to check genomic DNA carryover in RNA.
Reaction conditions for cDNA synthesis were 25°C for
5 minutes, 42°C for 50 minutes and 85°C for 5 minutes.
Equal amounts of cDNA were subsequently used for
amplification in a 50 μl PCR reaction using Emeral-
dAmp PCR Master Mix (Takara, Japan), containing Taq
polymerase, dNTPs, buffer and primers targeting β1-
adrenergic receptor, β2-adrenergic receptor and β3-
adrenergic receptor. PCR was performed with an initial
denaturation step at 94°C for 3 minutes, followed by de-
naturation at 94°C for 30 seconds, annealing (60°C for β1-
AR; 58°C for β2-AR; 61°C for β3-AR each for 30 seconds)
and extension at 72°C for 1 minute. GAPDH was used as
quantitative control in each PCR reaction. The PCR pro-
ducts were separated on 1.5% agarose gels and visualized
using ethidium bromide staining under UV transillumin-
ation. Primers sequences of β1-AR, β2-AR and β3-AR are
given in the Table 1.Western Blot analysis
Human retinal endothelial cells were lysed, centrifuged
and proteins were extracted according to the manufac-
turer’s protocol (Sigma). Bradford assay (Bio-Rad Labora-
tories) was used to quantify the protein concentrations in
the supernatants. 30 μg proteins of the lysate from high
glucose and low glucose were loaded in each well and sep-
arated on 10% SDS-PAGE (Precast gels, Bio-Rad, cat no
456-1093). Gels were electrophoretically transferred to
nitrocellulose membranes and blocked for 60 min with
Tris-buffered saline (TBS) containing 5% nonfat milk
(Bio-Rad, USA, cat no 170-6404) and 0.1% Tween-20.
Blots were incubated overnight at 4°C with primary anti-
bodies (1:3000) against β1-adrenergic receptor (Santa
Cruz, sc-568), β2-adrenergic receptor (Santa Cruz, sc-569)
and β3-adrenergic receptor (Santa Cruz, sc-1472). Anti-β-
actin (sc-7210) antibodies were used to ensure the quality
of protein separation and loading contents. After extensive
washes, the membranes were incubated with HRP-
conjugated IgG secondary antibodies (Santa Cruz, sc-
2004) and visualized with enhanced chemiluminescence
(Amersham Life Sciences, UK) using gel imaging system
(Biospectrum 410, UVP).
Terminal deoxynucleotidyl transferase dUTP nick end
labeling (TUNEL) assay
DNA damage was investigated and quantified with a col-
orimetric apoptosis detection kit (Titer TACS; R&D Sys-
tem) according to the manufacturer’s protocol. Kit
contained TUNEL staining in a 96-well format. Retinal
endothelial cells were cultured in medium containing
5 mM (normal) and 25 mM (high) glucose. Cells were
then transferred into a 96-well plate (1 × 105 cells/well)
and fixed with 3.7% buffered formaldehyde for 5 minutes
followed by washing with PBS. Washing was followed by
permeabilization of cells with 100% methanol for 20 mi-
nutes (at room temperature) and again washing with
PBS. Following the manufacturer’s instructions, cells
were then subjected to labeling procedure and the reaction
was stopped with 0.2 N HCl after 30 minutes. Nuclease
treated control was used to confirm the permeabilization
and labeling reaction. The absorbance was measured at
450 nm with microplate reader.
Dichloro-dihydro-fluorescein diacetate (DCFH-DA) assay
The intracellular ROS (reactive oxygen species) was mea-
sured by using 2′7′-dichloro-dihydro-fluorescin diacetate
(DCFH-DA) reagent. The DCFH-DA enters through the
cell membrane and enzymatically hydrolyzed by intracel-
lular esterases to non-fluorescent dichlorofluorescin-
diacetate (DCFHDA), which is then oxidized to highly
fluorescent dichlorofluorescin (DCF) in the presence of
intracellular reactive oxygen species. Retinal endothelial
cells were seeded in 96-well black plates and allowed to
Table 1 RT-PCR and methylation primers
Gene names RT-PCR primers Methylation primers
β1-AR F: 5′-GGCAGCTGCTATTTCTGTCC-3′ F: 5′-GGATTGGTTGTAGGAGTTTGA-3′
R: 5′-TCTGGACCAGTTCTGCCTCT-3′ R: 5′-TAAAAAACACCCCAAAAACCC-3′
β2-AR F: 5′-ACAAACTATCCAGCAGATGAAAGG-3′ F: 5′-GGGTTAGTTTTAGGAGAAGGAGG-3′
R: 5′-AGCGGGGGTATGCAAGTATG-3′ R: 5′-ATACCTACCAATTCCAACCC-3′
β3-AR F: 5′-CCCACTTTCCCTCCGTTTGT-3′ F: 5′-GATTTGGTGATGGGATTTTTG-3′
R: 5′-GAGTTTCAGGAAGGGTGGGG-3′ R: 5′-CCACCACTAACTCATAATAAAC-3′
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tional 24 hours in media containing 5 mM (normal)
and 25 mM (high) glucose. Cells were then treated with
5 μM DCFH-DA and the readings were taken at
485 nm excitation and 530 nm emission in a fluores-
cence plate reader. To calculate the amount of intracel-
lular ROS produced, the mean control was subtracted
from the mean experimental group.
8-OHdG ELISA assay
8-Hydroxy-2′-deoxyguanosine (8-OHdG), one of the
DNA lesions has been studied extensively as a marker of
oxidative stress-mediated DNA damage, was estimated
in retinal endothelial cells treated with high glucose,
normal glucose and H2O2 as a control, using Oxiselect
oxidative DNA damage ELISA kit (Cell Biolabs). Cells
were grown and treated with high glucose (25 mM), nor-
mal glucose (5 mM) and H2O2 (50 mM) as a control.
The whole experiment was performed as previously re-
ported with minor modifications [33].
Selection of upstream and downstream sequences within
CpG Islands
DNA sequences of CpG islands in β1-adrenergic recep-
tor (2161 bp), β2-adrenergic receptor (807 bp) and β3-
adrenergic receptor (1522 bp) were retrieved from NCBI
and UCSC genome browser. Promoter region of each
gene from upstream -499 bp to downstream 100 bp,
relative to CpG contents and transcription start sites,
were identified using Eukaryotic Promoter Database
(EPD). Subsequently, primers were designed within -499
to 100 bp region of each promoter with products con-
taining 40 CpGs in β1-adrenergic receptor , 16 CpGs in
β2-adrenergic receptor and 27 CpGs in β3-adrenergic
receptor (Figure 1A, B and C).
DNA extraction, bisulfite treatment and PCR amplification
DNA was extracted from retinal endothelial cells grown
in high and normal glucose using genomic DNA mini
kit (Invitrogen USA, Cat no K1820-02) according to the
manufacturer’s protocol. 500 ng of DNA was bisulfite-
converted with Zymo EZ DNA methylation kit (cat no
D5005, USA). PCR was used to amplify the bisulfite
modified DNA using hot start taq DNA polymerase andbisulfite primers targeting the promoters of β1, β2 and
β3-adrenergic receptors. PCR reaction conditions were
set as 5 minutes at 95°C; 40 seconds at 95°C, 1 minute
at 60°C and 1 minute at 72°C; and a 7 minutes final ex-
tension at 72°C. PCR products were analyzed on 2%
agarose gel and purified using mini elute gel extraction
kit (Qiagen, Cat no 28604) according to the manufac-
turer’s instructions.
Cloning and transformation
The purified products were ligated into pCR2.1 vector using
TOPO TA Cloning Kit (Invetrogin). 4 μl of PCR product
and 1 μl of TOPO vector, with a final volume of 6 μl were
gently mixed and incubated at room temperature for 5 mi-
nutes. Cloning reaction was added to chemically competent
DH5α, mixed and incubated on ice for 10 minutes. Then
subjected the cells to heat shock the cells for 30 seconds at
42°C and again transferred to ice. 250 μl S.O.C medium
was added (provided with kit, invitrogen), spread each
transformation onto pre-warmed LB plates (ImMedia Amp
Blue, Invitrogen USA) and incubated overnight at 37°C.
pUC19 DNA was used as control.
Sequencing and Methylation analysis
After blue-white screening, colonies (10 colonies for each
β1, β2 and β3-adrenergic receptors) containing the insert
were isolated and cultured overnight in ImMedia Amp Li-
quid (Invitrogen, USA). Favorgen plasmid extraction kit
(cat no FAPDE100) was used to purify the plasmids from
each colony, which were then sent for sequencing. After
sequencing, UCSC genome browser, NCBI, Ensembl
and QUMA (Quantification tool for methylation ana-
lysis) were used to align, visualize and quantify the bi-
sulfite sequence data for CpG methylation of β1, β2
and β3-adrenergic receptors. The regions examined in
all genes were located within CpG islands as shown in
the Figure 2A, B and C.
Statistical analysis
All experiments were performed at least 3 times. The re-
sults were reported as mean SD. Student t test was used
to determine statistical significance. A value of 0.05 was
considered as significant. SPSS and graphpad prism soft-
wares were used for analysis.
Figure 1 Promoter DNA sequences of β1, β2 and β3-adrenergic receptors from -499 to 100 bp. Relative to CpG contents and transcription
start sites, sequences were retrieved from Eukaryotic Promoter Database (EPD). Arrows indicate forward and reverse primers that amplify regions
containing 40 CpGs in β1-adrenergic receptor (A), 16 CpGs in β2-adrenergic receptor (B) and 27 CpGs in β3-adrenergic receptor (C).
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Adrenergic receptors β1 and β3 expression in retinal
endothelial cells
Adrenergic receptors β1 and β3 were expressed in retinal
endothelial cells both under high and normal glucose
conditions. First immunocytochemistry was carried out
(Figure 3A) and then reverse transcription was performed
to confirm the presence of β1, β2 and β3-adrenergic re-
ceptors which revealed no expression of β2-adrenergic
receptor but relatively high expression of β1 and β3-
adrenergic receptors (Figure 3C and D). To reconfirm the
expression of target genes, mRNA measurement by re-
verse transcription was followed by Western Blotting. In
Western Blotting analysis, β1 and β3-adrenergic receptors
were expressed in the same manner as previously detected
by RT-PCR analysis (Figure 3E and F).
β3-Adrenergic receptor is differentially expressed in
retinal endothelial cells under hyperglycemic conditions
Gene expression of β1, β2 and β3-adrenergic receptors
were compared within the same endothelial cells, grown
in high (25 mM) and normal (5 mM) glucose levels.Expression of β3-adrenergic receptor in high glucose
was significantly (p < 0.05) different than the expression
of the same gene in normal glucose at both protein and
mRNA levels (Figure 3C, D, E and F).
Adrenergic receptor β1 is not differentially expressed in
retinal endothelial cells while β2-adrenergic receptor is not
detectable both under normal and high glucose levels
According to the results obtained from protein and mRNA
analysis, the expression of β1-adrenergic receptor was not
significantly different both in high and normal glucose con-
ditions (p = 0.8544). β2-adrenergic receptor was not detec-
table at mRNA level as well as protein level, however very
small and defused bands were seen when retinal endo-
thelial cells were grown under hyperglycemic condition
(Figure 3C and E).
Promoter methylation and its association with the
expression of β1, β2 and β3-adrenergic receptors in
retinal endothelial cells
According to our data, β1-adrenergic receptor showed
no significant difference in promoter methylation when
Figure 2 Percent methylation of upstream and downstream sequences. CpG islands and the sites which were amplified, bisulfite converted
and sequenced for β1-adrenergic receptor (A), β2-adrenergic receptor (B) and β3-adrenergic receptor (C).
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We evaluated 40 CpGs in the promoter of β1-adrenergic
receptor which showed 26.5% methylation in high glucose
and 24.5% methylation in normal glucose (Figure 4A, B
and C). Our results indicate no significant association of
promoter methylation and expression of β1-adrenergic
receptor in human retinal endothelial cells cultured
under hyperglycemic conditions (Figure 5A). β2-adrenergic
receptor showed 53.7% and 55% methylation in high
and normal glucose respectively. Although the differ-
ence in high and normal glucose did not achieve signifi-
cance, hypermethylated promoter patterns show that
β2-adrenergic receptor gene is silenced in retinal endo-
thelial cells possibly due to hypermethylation of its
promoter (Figure 4D, E and F). Promoter methylation
of β3-adrenergic receptor was significantly different
(p < 0.01) with 13.3% and 33.7% methylation in high
and normal glucose respectively, having an inverse cor-
relation with its expression (Figure 4G, H and I). Inter-
estingly the expression of β3-adrenergic receptor was
also significantly different both at mRNA (p < 0.05) and
protein (p < 0.01) levels in high and normal glucoseconditions. Total 27 CpGs were included in from the
promoter of β3-adrenergic receptor.
A graphical presentation of CpGs in 10 samples of each
gene is shown in Figure 6 with black bars for methylated
and white bars for unmethylated CpGs at a certain position.
β1-adrenergic receptor shows maximum CpG methylation
at position 32, 186, 198 and 270 in high glucose (Figure 6A)
while in normal glucose the high occurrence of methylation
was seen at position 123, 186 and 220(Figure 6B). In
β2-adrenergic receptor methylation was high at position
66, 78, 100 and 162 (Figure 6C) and 68, 104, 109, 155 and
167 (Figure 6D) in high and normal glucose respectively.
β3-adrenergic receptor revealed high methylation at pos-
ition 217 in high glucose while at position 72 and 150 in
normal glucose.
Oxidative stress, apoptosis and promoter methylation of β1,
β2 and β3-adrenergic receptors in retinal endothelial cells
Reactive oxygen species (ROS) production was significantly
high (p < 0.001) in retinal cells grown in high glucose
(25 mM) compared to normal (5 mM) glucose concentra-
tion as shown in Figure 5E, F and G. ROS production in
Figure 3 Amplification of CT converted DNA and expression analysis. (A) Immunocytochemistry of β-adrenergic receptors, showing strong
expression of β1and β3-adrenergic receptors. (B) Amplification of CT converted DNA using bisulfite converted primers for β1, β2 and β3-adrenergic
receptors. (C) Expression levels of β1, β2 and β3-adrenergic receptors genes by reverse transcription, in high and normal glucose conditions. GAPDH
was used as a loading control while cDNA without Reverse Transcriptase was used as negative control. (D) Graphical presentation of β1, β2 and
β3-adrenergic receptors expression of mRNA (E) Expression of β1, β2 and β3-adrenergic receptors at protein level by Western Blotting in high and
normal glucose. (F) Graphical presentation of relative expression of β1, β2 and β3-adrenergic receptors genes in retinal endothelial genes.
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β3-adrenergic receptor promoter in high glucose, suggest-
ing that DNA damage by increased ROS production may
induce loss of methylation under hyperglycemic condi-
tion. β2-adrenergic receptor showed the same pattern
of methylation and ROS production in high glucose;
however CpG methylation in high and normal glucose
was not significantly different (Figures 4D and 5B).
Apoptosis in high glucose was also significantly higher(p < 0.005) as compared to normal glucose and was posi-
tively correlated with the extent of ROS production.
Diabetes mellitus is associated with oxidative stress,
leading to protein, lipid and DNA modifications. Oxidative
DNA damage is usually evaluated by measuring 8-OHdG
(8-hydroxy-2-deoxy-guanosine). In our results 8-OHdG
level was significantly (p < 0.05) higher in high glucose as
compared to normal glucose. For β3-adrenergic receptor,
DNA damage was inversely proportional to the level of
Figure 4 Methylation analyses. Methylation (black dots) of β1-adrenergic receptor (A and B in high and normal glucose respectively), β2-adrenergic
receptor (D and E in high and normal glucose respectively) and β3-adrenergic receptor (G and H in high and normal glucose respectively), using
QUMA (Quantification tool for methylation analysis). Empty C, F and I show methylation of each colony.
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Upstream and downstream promoter methylation of
adrenergic receptors is not significantly different except
β1-adrenergic receptor in high glucose and β3-adrenergic
receptor in normal glucose
Over all in this study, no significant association was found
in methylation between upstream and downstream TSS
except β1-adrenergic receptor in high glucose (p < 0.005)
and β3-adrenergic receptor in normal glucose (p < 0.005).
Upstream and downstream promoter methylation of
β1-adrenergic receptor were 27.2% and 16.6% in high
glucose, while 18.1% and 13.3% in normal glucose re-
spectively. β2-adrenergic receptor showed 54.6% and
50% methylation values in high glucose while 55.1.7%
and 60.6% methylation in normal glucose at upstream
and downstream CpGs respectively. At upstream anddownstream promoter sequences, methylation level of
β3-adrenergic receptor were 13.3% and 13.4% in high
glucose, while 34.1% and 26.3% in normal glucose
respectively.
Discussion
Diabetes and diabetogenic agents such as high glucose
and advanced glycation end-products have adverse effects
in major target cells including endothelial cells and vascu-
lar smooth muscle cells [34-36]. In diabetic retinopathy
hyperglycemia cause morphological and functional dam-
age to the retina through a number of mechanisms includ-
ing oxidative stress, proinflammatory cytokines and
increased TNFa signaling [37-41]. According to the pub-
lished reports, β-adrenergic receptors are likely to play a
significant role in potentiating retinal endothelial cells
against hyperglycemia and hyperglycemia-induced oxida-
tive stress. The oxidative stress-induced damage is not
Figure 5 Percent methylation of β1-AR (A), β2-AR (B) and β3-AR (C). β3-AR shows a significantly higher methylation in normal glucose
conditions (p < 0.01). (D) shows terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay that demonstrates a significantly high
(p < 0.005) apoptosis of retinal endothelial cells grown in hyperglycemia. (E, F and G) show Dichlorodihydrofluorescein diacetate (DCFH-DA) assay
showing a high production (p < 0.001) of reactive oxygen species (ROS) in retinal endothelial cells that were grown in high glucose (25 mM)
condition (F), while low production in cells grown in normal glucose (5 mM) condition (G). 8-OHdG level in high and normal glucose (H) where
H2O2 was used as control.
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ing DNA, protein, free fatty acids and lipids, but may ex-
tend to the ability of oxidative stress to alter gene
expression. Thus we sought to investigate whether hyper-
glycemia induced oxidative stress and apoptosis can influ-
ence β-adrenergic receptors methylation and expression
in retinal endothelial cells.
DNA methylation is an important genetic mechanism
that plays an essential role in the regulation of gene expres-
sion in various diseases such as diabetes, cancer, musculardystrophy and a range of birth defects, but a comprehen-
sive understanding of the diversity of the mechanisms in-
volved in methylation is not understood [42]. Despite
limited data on the epigenetic regulation and its association
with the disease progression, the underlying relationship
between changes in promoter DNA methylation and differ-
ences in gene regulation are well established [43,44]. Previ-
ous studies have provided evidence which link gene
methylation and transcription in a number of genes and
tissue specific cell lines; however methylation studies on G
Figure 6 Graphical presentation of CpGs in 10 samples of each gene. Black bars show methylated while white bar show unmethylated CpGs
at a certain position. In β1-adrenergic receptor there are 40 CpGs as shown by A (high glucose) and B (lnormal glucose) while in β2-adrenergic
receptor there are 16 CpGs (C and D, high glucose and normal glucose respectively). E and F show methylated and unmethylated CpGs in
β3-adrenergic receptor in high and normal glucos respectively.
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receptors in particular are very limited. We know very little
about the changes in epigenetic profiles of β-adrenergic re-
ceptors that might explain differences in gene expression.
DNA methylation, especially CpG methylation at promoter
regions, has been an important modification that prevents
transcriptions factors (TF) recruitment and consequently
suppresses the transcription of various genes. Promoter
methylation is considered a key regulator of biological pro-
cesses such as suppression of transposable elements, X-
chromosome inactivation and genomic imprinting. CpG
dependent transcription factor binding is a prominent fea-
ture and provides support to understand the role and
mechanism of TFs in epigenetic regulation [45]. Varioustranscription factors including E2F, HIF-1, and c-myc bind
to sequences containing CpGs in the promoters [46,47].
Methylation does not interfere only in transcription factor
binding activity, but also modulates chromatin structure by
modifying the interaction between core histones and DNA.
Previous studies show that Sp1 binding to its cognate se-
quence in certain genes is affected by methylation [48]. Β-
adrenergic receptors contain special sites such as TATA
box, CAAT box, mRNA cap sites and GC rich sites where
TF Sp1 binds [49]. In a recent study, Mu et al. found that
β2-adrenergic receptor stimulation led to decreased tran-
scription of the gene encoding WNK4. Stimulation of β2-
adrenergic receptor caused cAMP-dependent inhibition of
histone deacetylase-8 (HDAC8) activity, increased histone
Safi et al. BMC Medical Genomics 2014, 7:29 Page 11 of 13
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receptor to a negative glucocorticoid responsive element
in the promoter region [50]. For our results, we also
hypothesize that hypermethylation of β2-adrenergic recep-
tor might prevent the core transcription factors such as
Sp1 to bind with its promoter and hence causing halted ex-
pression of β2-adrenergic receptor.
In our study, protein and mRNA expression of β1 and
β3-adrenergic receptors were confirmed in retinal endo-
thelial cells however β2-adrenergic receptor was hard to
detect both at mRNA and protein levels. According to
several studies including our previous unpublished data,
hyperglycemia increases the oxidative stress in several cell
lines. Kong et al. and Takahata et al. in two different stu-
dies found that upregulation of β3-adrenergic receptor is
associated with increased oxidative stress [51] while func-
tional expression of β2-adrenergic receptor is responsible
for protection against oxidative stress through promotion
of glutathione synthesis [52]. In 2003, Steinle et al. re-
ported that β3-adrenergic receptor mediates migration
and proliferation of retinal endothelial Cells. They Used
BRL37344 agonist to stimulate the β3-adrenergic receptors
on retinal endothelial cells and showed that these recep-
tors could express in retinal endothelial cells. They re-
ported that BRL37344-mediated migration could be
alienated by prior inhibitors administration of Akt, PI3K,
MEK and MMP-2/MMP-9 and hypothesized that PI3K
may directly be linked to the β3-adrenergic receptor [53].
These studies led us to question whether our hypergly-
cemic endothelial cells with no agonist (BRL37344) and
increased oxidative stress would differentially mediate the
promoter methylation and expression of β3, β2 and β1-
adrenergic receptors. In our study, hyperglycemic endo-
thelial cells had significantly higher oxidative stress and
consequently a higher expression of β3-adrenergic re-
ceptor. Methylation in β3-adrenergic receptor was sig-
nificantly low in cells with significantly high apoptosis
and oxidative stress as per our hypothesis.
There is an exquisite interrelationship between methyla-
tion and oxidative stress. Glutathione is depleted by the
excess of oxidative stress; consequently impairing the one-
carbon cycle and causes undermethylation. However on
the other hand glutathione, cysteine, and metallothionein
get depleted by undermethylation with oxidative stress
overload. Increased production of ROS can directly or in-
directly cause a wide range of DNA lesions including base
modifications, strand breakage, deletions and chromo-
somal rearrangements. Such alterations have been shown
to impede the ability of DNA to function as a substrate
for the DNA methyl transferases (DNMTs), resulting in
global hypomethylation [54-56]. In our data β3-adrenergic
receptor is hypomethylated with increased expression.
The reason behind hyperglycemia led increase in β3-
adrenergic receptor is not clear however Walker andSteinle suggest that the level of norepinephrine are signifi-
cantly reduced as early as 1 week after streptozotocin
(STZ) treatment, this loss of norepinephrine may conse-
quently lead to denervation supersensitivity and increased
expression of β1-adrenergic receptor in Muller cells [33].
Hypermethylation and low expression of β2-adrenergic re-
ceptor is another interesting finding in our study. In our
study we selected upstream and downstream regions,
however high and normal glucose induced no variation
and no association was seen in methylation between up-
stream and downstream sequences except β1-adrenergic
receptor in high glucose and β3-adrenergic receptor in
normal glucose.
Conclusion
Our study demonstrates that β1 and β3-adrenergic recep-
tors β-ARs expressed in human retinal endothelial cells
HREC. Oxidative stress and apoptosis are inversely propor-
tional to the extent of promoter methylation, suggesting
that methylation loss might be due to oxidative stress-
induced DNA damage. Collectively this study may help in
understanding the pathophysiology of diabetic retinopathy
and epigenetic regulation of β-adrenergic receptors.
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